Zydus, Lupin Partner to Co-Market Diabetes Drug Semaglutide in India

• Zydus Lifesciences and Lupin have signed a licensing and supply agreement to co-market the diabetes treatment drug Semaglutide Injection (15 mg/3 ml) in India.
• The partnership aims to enhance patient access to advanced diabetes and weight management therapies using a patient-friendly reusable pen device.
• Lupin will market Semaglutide under the brand names Semanext and Livarise, while Zydus will use Semaglyn, Mashema, and Altermet.
• Lupin will pay Zydus upfront licensing fees and milestone payments based on pre-defined achievements.
• Semaglutide is indicated for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, and for chronic weight management.